US FDA grants first breakthrough drug therapy designation; more awards may be imminent
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has granted its first breakthrough therapy designation to a drug under a provision of the Food and Drug Administration Safety and Innovation Act (FDASIA), which aims to expedite the development and review processes for medicines intended to treat serious or life-threatening diseases1,.